Carvedilol Tablet, Film Coated
Product Images NDC 70518-4389

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 70518-4389). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Carvedilol 12.5 mg film coated tablets packaging label, showing a quantity of 30 tablets. Label includes NDC 70518-4389-00, round white tablet description with imprint ZC41, repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer noted is BluePoint Labs, Ahmedabad, India. Storage and safety instructions are also present.*

FDA Label Image

Structured Formula For Carvedilol (Image 01)

Chemical structure diagram of Carvedilol, showing its molecular arrangement including aromatic rings and functional groups relevant to the active pharmaceutical ingredient.*

FDA Label Image

Figure 3 (Image 02)

A line graph depicting percentage mortality on the y-axis against months on the x-axis. Two lines represent mortality trends for placebo and carvedilol groups, with a p-value of 0.03 indicating statistical comparison of mortality between groups over a 24-month period.*

FDA Label Image

Figure 4 (Image 03)

A dual-panel hazard ratio plot comparing different patient subgroups. The left panel shows hazard ratios for factors such as age, gender, post-myocardial infarction timing, prior IV/oral beta-blocker use, Killip classification, thrombolysis status, and PTCA for MI, each with confidence intervals. The right panel shows hazard ratios for factors including congestive heart failure status, diuretics use, angina, hypertension, diabetes, heart rate, and systolic blood pressure, also with confidence intervals. The plot is used to assess risk variation across these clinical parameters.*

FDA Label Image

Figure 1 (Image 04)

A line graph comparing percentage mortality over 24 months for Carvedilol versus placebo. The x-axis shows months, while the y-axis indicates percent mortality. The Carvedilol line shows consistently lower mortality than placebo, with a noted p-value of 0.0014 indicating statistical significance.*

FDA Label Image

Figure 2 (Image 05)

A forest plot chart showing hazard ratios with confidence intervals for various patient subgroups including gender, age, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use, culminating in a summary point for all patients. The horizontal axis ranges from 0.0 to 2.0, with a vertical dashed line at 1.0 indicating the reference hazard ratio.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.